AARD

Aardvark Therapeutics, Inc.

$1.59

16.06%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-71.3%
3M-76.5%
YTD-88.6%
1Y-87.4%
52-week range—
Beta2.07
Full chart and returns against a benchmark

Q-Score

28/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk32
Performance31
Valuation30
Profitability—
Leverage47
Sentiment54
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$57.6M
Net margin—
Historical fundamentals

Valuation

AARDIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.476.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report
EPS estimate$-0.75
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate